Please assess the completion status of the following clinical trial:

Trial Title: Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Donors must satisfy standards including those set forth by FACT (Foundation for the Accreditation of Cellular Therapy) and the criteria specified in FDA 21 Code of Federal Regulations (CFR) 1271. Specifically, screening for risk factors for communicable disease as well as infectious disease screening by serologic and PCR testing as outlined below. Including testing for IV, Hepatitis B, Hepatitis C, HTLV I and II, CMV, EBV, and toxoplasmosis, westnile virus, syphilis, varicella zoster, and Chagas disease.~* Donors must be typed for HLA-A, B, C, DR and DQ at high resolution.~* Donors accrued at MSKCC must have a hemoglobin value \> 10g/dl~* Donors must be capable of undergoing, at least, a single standard 2 blood volume leukapheresis or a donation of one unit of whole blood~* Donors must weight \>/= 25 kg~Exclusion Criteria:~* HTLV/HIV (+) or Hepatitis B or C positive donors~* Donors who are pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Consenting healthy donor (Type: None): Transplant and healthy HLA typed donors

Based on this trial design, predict the completion outcome and termination type (if applicable).